EYPT Logo

EyePoint Pharmaceuticals, Inc. (EYPT) 

NASDAQ
Market Cap
$604.02M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
3 of 971
Rank in Industry
2 of 557

Largest Insider Buys in Sector

EYPT Stock Price History Chart

EYPT Stock Performance

About EyePoint Pharmaceuticals, Inc.

EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. It also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

Insider Activity of EyePoint Pharmaceuticals, Inc.

Over the last 12 months, insiders at EyePoint Pharmaceuticals, Inc. have bought $89.68M and sold $120.66M worth of EyePoint Pharmaceuticals, Inc. stock.

On average, over the past 5 years, insiders at EyePoint Pharmaceuticals, Inc. have bought $29.98M and sold $43.05M worth of stock each year.

Highest buying activity among insiders over the last 12 months: Cormorant Asset Management, LP (10 percent owner) — $1.52B. Zaderej Karen L. (director) — $199,500. ANDO GORAN (director) — $39,750.

The last purchase of 5,000 shares for transaction amount of $39,750 was made by ANDO GORAN (director) on 2024‑08‑21.

List of Insider Buy and Sell Transactions, EyePoint Pharmaceuticals, Inc.

2024-08-21Purchasedirector
5,000
0.0082%
$7.95$39,750-1.10%
2024-08-20Purchasedirector
2,567
0.0048%
$7.79$19,997+16.00%
2024-08-19Purchasedirector
12,500
0.0235%
$7.98$99,750+12.72%
2024-08-16Purchasedirector
3,173
0.0057%
$7.88$25,0030.00%
2024-07-12Saledirector
11,625
0.0274%
$10.06$116,9950.00%
2024-06-03Saledirector
11,625
0.0233%
$10.30$119,705-9.11%
2024-05-14Saledirector
11,625
0.0227%
$12.65$147,045-26.95%
2024-05-06Purchase10 percent owner
850,000
1.8064%
$11.86$10.08M-18.68%
2024-04-18Purchase10 percent owner
581,765
1.2029%
$18.03$10.49M-47.46%
2024-02-02SaleSVP & Chief Commercial Officer
209
0.0007%
$28.49$5,954-61.15%
2024-01-26SaleSVP & Chief Commercial Officer
26,017
0.0509%
$25.38$660,370-57.91%
2024-01-26SaleChief Medical Officer
49,325
0.0975%
$25.66$1.27M-57.91%
2024-01-25SaleSVP & Chief Commercial Officer
600
0.0012%
$25.00$15,000-54.81%
2024-01-25SaleChief Medical Officer
600
0.0012%
$25.00$15,000-54.81%
2024-01-24SaleExecutive Vice Chair
29,956
0.0887%
$24.98$748,250-52.49%
2024-01-24SaleSVP & Chief Commercial Officer
11,300
0.0335%
$25.01$282,621-52.49%
2024-01-24SaleChief Medical Officer
11,251
0.0334%
$25.01$281,415-52.49%
2024-01-23SaleExecutive Vice Chair
5,044
0.0144%
$24.97$125,950-53.90%
2024-01-23SaleSVP & Chief Commercial Officer
900
0.0026%
$25.00$22,500-53.90%
2024-01-23SaleChief Medical Officer
5,135
0.0146%
$25.00$128,375-53.90%

Insider Historical Profitability

6.64%
Cormorant Asset Management, LP10 percent owner
8325000
12.1976%
$8.8560
Ocumension Therapeuticsdirector
100221
0.1468%
$8.8503
Liu Yedirector
100221
0.1468%
$8.8504
Lurker Nancydirector
97635
0.1431%
$8.8544<0.0001%
Jones David ScottSVP & Chief Commercial Officer
37962
0.0556%
$8.8506
Paggiarino Dario A.Chief Medical Officer
36505
0.0535%
$8.8507
Zaderej Karen L.director
16500
0.0242%
$8.8510
ANDO GORANdirector
13150
0.0193%
$8.8510
DICICCO WENDY Fdirector
9967
0.0146%
$8.8510
Pine Michael CraigChief Corp Dev.&Strat. Officer
4343
0.0064%
$8.8511<0.0001%
GUYER DAVID Rdirector
1850
0.0027%
$8.8503
EW Healthcare Partners, L.P.10 percent owner
3490921
5.1148%
$8.8529+60.73%
Ashton PaulPresident & CEO
440741
0.6458%
$8.85012
Freedman LoriVP Corp. Affairs, GC and Sec
96423
0.1413%
$8.8505
Elston GeorgeChief Financial Officer
40000
0.0586%
$8.8540+18.73%
Landis John B.director
40000
0.0586%
$8.8510<0.0001%
Godshall Douglas Evandirector
29500
0.0432%
$8.8510<0.0001%
Duker Jay S.director
17500
0.0256%
$8.8510<0.0001%
Hopper Pauldirector
10000
0.0147%
$8.8510+38.89%
Ross Leonard SVice President, Finance
0
0%
$8.8504

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Cormorant Asset Management Lp$142.48M13.246.89M+14.16%+$17.67M6.64
Adage Capital Partners Gp L L C$98.31M9.134.76M+6.49%+$5.99M0.18
Suvretta Capital Management, LLC$77.8M7.233.76M-7.22%-$6.06M3.29
Franklin Templeton Investments$70.06M6.513.39M-26.97%-$25.87M0.02
BlackRock$57.61M5.352.79M+28.49%+$12.78M<0.01
T. Rowe Price$50.97M4.732.47M-2.25%-$1.18M0.01
The Vanguard Group$49.53M4.62.4M+17.8%+$7.49M<0.01
Millennium Management LLC$42.3M3.932.05M+81.32%+$18.97M0.03
T Rowe Price Investment Management Inc$33.17M3.081.6M+2.96%+$952,654.720.02
Essex Woodlands Management Inc$32.07M2.981.55M-33.63%-$16.25M9.32
Citadel Advisors LLC$28.43M2.641.38M+12.08%+$3.06M0.02
Morgan Stanley$27.74M2.581.34M+1.76%+$479,916.09<0.01
Octagon Capital Advisors LP$22.6M2.11.09MNew+$22.6M0.12
State Street$21.34M1.981.03M+87.53%+$9.96M<0.01
RA Capital Management, L.P.$19.4M1.8938,591New+$19.4M0.02
Goldman Sachs$17.35M1.61839,478+47.8%+$5.61M<0.01
Deutsche Bank$17.27M1.61835,722+8.46%+$1.35M0.01
Geode Capital Management$17.21M1.6832,637+22.01%+$3.11M<0.01
Ameriprise Financial$13.92M1.29673,348-56.17%-$17.83M<0.01
Fiera Capital$13.87M1.29671,118New+$13.87M0.04
FINEPOINT CAPITAL LP$13.57M1.26656,600New+$13.57M2.18
Federated Hermes$13.29M1.24643,176-4.69%-$654,164.160.03
Laurion Capital Management LP$13.01M1.21629,396-0.63%-$82,948.710.09
Perceptive Advisors$12.19M1.13589,6460%+$00.01
Deerfield Management$11.98M1.11579,594New+$11.98M0.03
Woodline Partners LP$9.92M0.92479,682+19.92%+$1.65M0.09
Oracle Investment Management Inc$9.55M0.89461,857+15.02%+$1.25M1.29
UBS$9.44M0.88456,626-20.47%-$2.43M<0.01
Marshall Wace$8.04M0.75388,955New+$8.04M0.01
Candriam S C A$7.92M0.74383,000+173.57%+$5.02M0.05
Northern Trust$6.66M0.62322,225+34.47%+$1.71M<0.01
Schroder Investment Management Group$6.33M0.59306,206+70.11%+$2.61M0.01
SEB$5.85M0.54282,814New+$5.85M0.03
AXA$5.44M0.51263,335-8.29%-$492,111.320.02
Invesco$5.22M0.49252,593-12.4%-$739,159.30<0.01
Vr Adviser Llc$5.17M0.48250,0000%+$00.25
Silverarc Capital Management Llc$5.13M0.48247,968New+$5.13M0.05
Lord Abbett$5.01M0.47242,580-34.61%-$2.65M0.02
Jane Street Capital$4.44M0.41214,694+207.17%+$2.99M<0.01
New York State Common Retirement Fund$4.11M0.38198,760+823.99%+$3.66M0.01
Walleye Capital$3.86M0.36186,958New+$3.86M0.01
Bank of America$3.63M0.34175,404+123.6%+$2M<0.0001
PFM Health Sciences$3.53M0.33170,8710%+$00.1
Barclays$3.42M0.32165,687+3.79%+$124,959.26<0.01
Connor Clark & Lunn Investment Management Ltd$3.41M0.32165,112+33.41%+$854,663.150.01
Nuveen$3.24M0.3156,573+26.74%+$682,750.79<0.01
BNY Mellon$3.19M0.3154,504+19.21%+$514,557.90<0.01
ESSEX INVESTMENT MANAGEMENT CO LLC$3.1M0.29149,819+1.54%+$47,086.260.62
Alyeska Investment Group L P$3.06M0.28147,837-20.88%-$806,192.060.02
Prudential Financial$3.04M0.28147,265+21.61%+$540,933.98<0.01
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.